N-[5-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]pyridin-2-yl]-N-(pyridin-4-ylmethyl)methanesulfonamide | 1333535-70-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: N-[5-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]pyridin-2-yl]-N-(pyridin-4-ylmethyl)methanesulfonamide
• CAS: 1333535-70-8
• 化学式: C₂₄H₂₈N₈O₂S
• 分子量: 492.605
• InChiKey: SLTWTVOINKYHIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1-cycloheptyl-6-(methylsulfonyl)-1H-pyrazolo[3,4-d]pyrimidine 在 potassium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 氯仿 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 N-[5-[(1-cycloheptylpyrazolo[3,4-d]pyrimidin-6-yl)amino]pyridin-2-yl]-N-(pyridin-4-ylmethyl)methanesulfonamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)

  摘要：

  A novel class of pyrazolopyrimidine-sulfonamides was discovered as selective dual inhibitors of aurora kinase A (AKA) and cyclin-dependent kinase 1 (CDK1). These inhibitors were originally designed based on an early lead (compound I). SAR development has led to the discovery of potent inhibitors with single digit nM IC(50)s towards both AKA and CDK1. An exemplary compound 1a has demonstrated good efficacy in an HCT116 colon cancer xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.06.129

文献信息

• Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I)
  作者：Lin Zhang、Junhua Fan、Jer-Hong Chong、Angela Cesena、Betty Y.Y. Tam、Charles Gilson、Christina Boykin、Deping Wang、Dikran Aivazian、Doug Marcotte、Guangqing Xiao、Jean-Yves Le Brazidec、Jinhua Piao、Karen Lundgren、Kevin Hong、Khang Vu、Khanh Nguyen、Liang-Shang Gan、Laura Silvian、Leona Ling、Min Teng、Mitchell Reff、Nicole Takeda、Noel Timple、Qin Wang、Ron Morena、Samina Khan、Shuo Zhao、Tony Li、Wen-Cherng Lee、Arthur G. Taveras、Jianhua Chao

  DOI：10.1016/j.bmcl.2011.06.129

  日期：2011.9

  A novel class of pyrazolopyrimidine-sulfonamides was discovered as selective dual inhibitors of aurora kinase A (AKA) and cyclin-dependent kinase 1 (CDK1). These inhibitors were originally designed based on an early lead (compound I). SAR development has led to the discovery of potent inhibitors with single digit nM IC(50)s towards both AKA and CDK1. An exemplary compound 1a has demonstrated good efficacy in an HCT116 colon cancer xenograft model. (C) 2011 Elsevier Ltd. All rights reserved.